DOI: 10.14704/nq.2018.16.12.1339

A Zebrafish Behavior Assay for Assessing Anti-Epileptic Drug Efficacy

Chongbin Liu, Zhiguo Xu, Yizhu Chen, Taotao Zhu, Rui Wang

Abstract


The availability of zebrafish larvae model of epileptic seizure provides opportunities to identify novel anticonvulsants for treatment of people with epilepsy. However, the major parameters of Zebrafishbehavior assay for assessing anti-epileptic drug efficacy existed disparity. In this study, we chose the high, medium, slow-speed moved distances and the total distances moved for seizure-like activity quantification in individual wells of a 48-well plate in the dark phase. Results also showed that the high-speed moved distances were given a more reasonable and sensitive dose-response curve than the total distances in zebrafish larvae model exposed to 10 mMpentylenetetrazole (PTZ). Moreover, this seizure-like swimming pattern was alleviated by the addition of either phenytoin (PHT) or valproate sodium (VPA), two commonly prescribed anti-epileptic drugs (AEDs). They exhibited concentration-dependent inhibition of both locomotor activity and PTZ-induced c-fostranscription, confirming their anticonvulsant characteristics. Whereas carbamazepine (CBZ) promoted zebrafish larvae movement by 26% at 30 μM and 116.7% at 100 μM, and sharply suppressed zebrafish larvae motility about 94.8% at 300 μM.C-fos expression significantly decreased at 30 μM and 300 μM CBZ, which was found to oppose various aspects of the PTZ-induced changes in activity. These results indicated that this zebrafish larvae model could be useful for studying drug efficacy, predicting drug targets and aiding our understanding of disease etiology.

Keywords


Disease Model, Epilepsy, Pentylenetetrazole, Seizure, Zebrafish Larvae

References


Stewart AM, Desmond D, Kyzar E, Gaikwad S, Roth A, Riehl R, Collins C, Monnig L, Gree J, Kalueff AV. Perspectives of zebrafish models of epilepsy: What, how and where next? Brain Res Bull 2012; 87: 135-143.

Pitkanen A and Lukasiuk K. Molecular and cellular basis of epileptogenesis in symptomatic epilepsy. Epilepsy Behav 2009; 14: 16-25.

Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure 2011; 20: 359-368.

Morimoto K, Fahnestock M, Racine RJ. Kindling and status epilepticus models of epilepsy: rewiring the brain. Prog Neurobiol 2004; 73:1-60.

Löscher W and Schmidt D. Modern antiepileptic drug development has failed to deliver: ways out of the current dilemma, Epilepsia 2011; 52: 657-678.

Kwan P, Arzimanoglou A, Berg AT, Brodie MJ, Allen Hauser W, Mathern G, Moshe SL, Perucca E, French J. Definition of drug resistant epilepsy: Consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 2010; 51: 1069-1077.

Berghmans S, Hunt J, Roach A, Goldsmith P. Zebrafish offer the potential for a primary screen to identify a wide variety of potential anticonvulsants. Epilepsy Res 2007; 75: 18-28.

Afrikanova T, Serruys AS, Buenafe OE, Clinckers R, Smolders I, de Witte PA, Crawford AD, Esquerra CV. Validation of the zebrafish pentylenetetrazol seizure model: locomotor versus electrographic responses to antiepileptic drugs. PLos one 2013; 8: 1-9.

Lee GH, Sung SY, Chang WN, Kao TT, Du HC, Hsiao TH, Safo MK, Fu TF. Zebrafish larvae exposed to ginkgotoxin exhibit seizure-like behavior that is relieved by pyridoxal-5’-phosphate, GABA and anti-epileptic drugs. Dis Models Mech 2012; 5: 785-795.

Ellis LD and Soanes KH. A larval zebrafish model of bipolar disorder as a screening platform for neuro-therapeutics. Behav Brain Res 2012; 233: 450-457.

Peterson RT and Macrae CA. Systematic approaches to toxicology in the zebrafish. Annu Rev Pharmacol Toxicol 2012; 52: 433-453.

Eliceiri BP, Gonzalez AM, Baird A. Zebrafish model of the blood-brain barrier: morphological and permeability studies. Methods Mol Biol 2011; 686: 371-378.

Jeong JY, Kwon HB, Ahn JC, Kang D, Kwon SH, Park JA, Kim KW. Functional and developmental analysis of the blood-brain barrier in zebrafish. Brain Res Bull 2008; 75: 619-628.

Baraban SC, Taylor MR, Castro PA, Baier H. Pentylenetetrazole induced changes in zebrafish behavior, neural activity and c-fos expression. Neuroscience 2005; 131: 759-768.

Hortopan GA, Dinday MT, Baraban SC. Spontaneous seizures and altered gene expression in GABA signaling pathways in a mind bomb mutant zebrafish. J Neurosci 2010; 30: 13718-13728.

CKimmel CB, Ballard WW, Kimmel SR. Stages of embryonic development of the zebrafish. Dev Dyn 1995; 203: 253-310.

Pack AM, Reddy DS, Duncan S, Herzog A. Neuroendocrinological aspects of epilepsy: important issues and trends in future research. Epilepsy Behav 2011; 22: 94-102.

Mussulini BH, Leite CE, Zenki KC, Moro L, Baggo S, Rico EP, Rosemberg DB, Dias RD, Souza TM, Calcagnotto ME, Campos MM, Battastini AM, de Oliveira DL. Seizures induced by pentylenetetrazole in the adult zebrafish: A detailed behavioral characterization. PLos one 2013; 8: 1-9.

Pineda R, Beattie CE, Hall CW. Recording the adult zebrafish cerebral field potential during pentylenetetrazole seizures. J Neurosci Methods 2011; 200: 20-28.

Wong K, Stewart A, Gilder T, Wu N, Frank K, Gaikwad S, Suciu C, Dileo J, Utterback E, Chang K, Grossman L, Cachat J, Kalueff AV. Modeling seizure-related behavioral and endocrine phenotypes in adult zebrafish, Brain Res 2010; 1348: 209-215.

Vermoesen K, Serruys AS, Loyens E, Afrikanova T, Massie A, Schallier A, Michotte Y, Crawford AD, Esguerra CV, de Witte PA, Smolders I, Clinckers R. Assessment of the convulsant liability of antidepressants using zebrafish and mouse seizure models. Epilepsy Behav 2011; 22: 450-460.

Orellana-Paucar AM, Serruys AS, Afrikanova T, Maes J, De Borggraeve W, Alen J, Leon-Tamariz F, Wilches-Arizabala IM, Crawford AD, de Witte PA, Esguerra CV. Anticonvulsant activity of bisabolene sesquiterpenoids of curcuma longa in zebrafish and mouse seizure models. Epilepsy Behav 2012; 24: 14-22.

Baxendale S, Holdsworth CJ, Meza-Santoscoy PL, Harrison MR, Fox J, Parkin CA, Ingham PW, Cunliffe VT. Identification of compounds with anti-convulsant properties in a zebrafish model of epileptic seizures. Dis Models Mech 2012; 5: 773-784.

Henry BL, Minassian A, Young JW, Paulus MP, Gever MA, Perry W. Cross-species assessments of motor and exploratory behavior related to bipolar disorder. Neurosci Biobehav Rev 2010; 34: 1296-1306.

Johannessen LC. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. CNS Drugs 2008; 22: 27-47.

Chang P, Orabi B, Deranieh RM, Dham M, Hoeller O, Shimshoni JA, Yagen B, Bialer M, Greenberg ML, Walker MC, Williams RS. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. Dis Models Mech 2012; 5: 115-124.

Arban R, Maraia G, Brackenborough K, Winyard L, Wilson A, Gerrard P, Large C. Evaluation of the effects of lamotrigine valproate and carbamazepine in a rodent model of mania. Behav Brain Res 2005; 158: 123-132.

Herrera DG, Robertson HA. Activation of c-fos in the brain. Progress Neurobiol 1996; 50: 83-107.

Hidaka N, Suemaru K, Takechi K. Inhibitory effects of valproate on impairment of Y-maze alternation behavior induced by repeated electroconvulsive seizures and c-fos protein levels in rat brains. Acta Med Okayama 2011; 65: 269-277.

So EL, Ruggles KH, Cascino GD, Ahmann PA, Weatherford KW. Seizure exacerbation and status epilepticus related to carbamazepine-10, 11-epoxide. Ann Neurol 1994; 35: 743-746.

Chen B, Wang JF, Hill BC, Young LT. Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-fos. Mol Brain Res 1999; 70: 45-53.

Nivoli AM, Murru A, Goikolea JM, Crespo JM, Montes JM, Gonzalez-Pinto A, Garcia-Portilla P, Bobes J, Saiz-Ruiz J, Vieta E. New treatment guidelines for acute bipolar mania: A critical review. J Affect Disord 2011; 129: 14-26.


Supporting Agencies





| NeuroScience + QuantumPhysics> NeuroQuantology :: Copyright 2001-2019